Related Experiment Videos
A new suggestion of the design of rational anticancer therapy: experimental studies in mice
Abstract:
In attempts to develop a rational anticancer strategy the same homologous tissue in 3 conditions were used side by side as targets: normal epidermis of the mouse back. Tween 60R-provoked benign epidermal hyperplasia, and carcinogen-provoked malignant condition. In contrast to the highest tolerated doses of the cytostatics conventionally used, the dose was stepwise decreased towards the subthreshold level. Then the smallest dose that caused the slightest detectable injury to the malignant cells was employed. The results show that the dose of the cytostatics (colchicine, and vinblastine sulfate) can be reduced to 1/12 if the drug is linked to dimethyl-sulfoxide (DMSO), a compound with unique hydrating and oxido-reducing properties. The cytostatic-DMSO complex acts selectively, sparing the viability of the normal and hyperplastic cells, but at the same time increasing the vulnerability of the malignant cells. The specific target for cytostatic-DMSO complex is the 3-dimensional cytoskeleton (the differentiation organelle) which is deranged in malignant cells. The measure causes a morbid swelling (20-fold, or more) of the cytoplasm which leads to collapse of the cytoskeleton, so that the marginal quantities of the cytostatics can exert their effects in the highly re-hydrated water matrix of the malignant cells. It is, moreover, probable that the doses of the cytostatic in DMSO could be further reduced to 1/100, or even to 1/1,000. The polarization microscopic technique reveals events down to the (sub)-molecular level. The cytological material comprises 930,000 karyokinetic assemblies and 14,522,600 corresponding nucleated non-dividing cells in various cutaneous conditions of 1,860 mice. The conclusions were drawn only when the differences between corresponding parameter pairs were statistically highly significant (P less than 0.001).
Insights
Linking cytostatics with dimethyl-sulfoxide (DMSO) significantly reduces required doses for anticancer therapy. This cytostatic-DMSO complex selectively targets malignant cells, sparing healthy tissues by disrupting the cytoskeleton.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Developing effective and less toxic anticancer strategies is crucial.
- Conventional cytostatic drugs require high doses, leading to significant side effects.
- Understanding drug delivery mechanisms can enhance therapeutic efficacy.
Purpose of the Study:
- To investigate the potential of linking cytostatics with dimethyl-sulfoxide (DMSO) for a novel anticancer approach.
- To determine if DMSO-linked cytostatics can selectively target malignant cells while sparing normal and hyperplastic tissues.
- To explore the mechanism of action of cytostatic-DMSO complexes on cellular structures.
Main Methods:
- Utilized normal, hyperplastic, and malignant mouse epidermal tissue as targets.
- Administered cytostatics (colchicine, vinblastine sulfate) at progressively reduced doses, including subthreshold levels.
- Employed cytostatics linked with dimethyl-sulfoxide (DMSO) and analyzed effects using polarization microscopy.
- Statistical analysis (P < 0.001) was performed on large sample sizes (1,860 mice, ~930,000 karyokinetic assemblies, ~14.5 million cells).
Main Results:
- Linking cytostatics with DMSO allowed dose reduction by up to 1/12, with potential for further reduction to 1/1,000.
- The cytostatic-DMSO complex selectively damaged malignant cells, sparing normal and hyperplastic cells.
- The complex targets the deranged cytoskeleton in malignant cells, causing cytoplasmic swelling and collapse.
- This mechanism enhances the vulnerability of malignant cells to even marginal drug quantities.
Conclusions:
- DMSO-linked cytostatics represent a promising, highly selective anticancer strategy.
- This approach significantly reduces drug dosage, potentially minimizing toxicity.
- The disruption of the cytoskeleton is a key mechanism for selective cancer cell destruction.